Patients
Th is multicenter, randomized, double-blind, placebo-controlled trial was conducted at 52 centers in 5 countries (United States, Canada, Germany, Romania, and Ukraine) between February 2008 and October 2009 (4 sites in Germany were activated but failed to recruit any patients). Th e institutional review board at each center approved the protocol. Patients gave written informed consent.
Eligible patients were at least 18 years of age and had a confi rmed diagnosis of ulcerative colitis. Patients had a Mayo Score of 4 -10 points ( 11 ) and mildly to moderately active disease on sigmoidoscopy (endoscopic subscore of at least 1) while receiving either oral mesalamine (or equivalent medications sulfasalazine, balsalazide, and olsalazine) for at least 4 weeks or no medical therapy.
Patients with Crohn ' s disease or indeterminate colitis, severe ulcerative colitis (Mayo Score of 11 or 12 points, toxic megacolon, toxic colitis), previous colonic surgery or probable requirement for intestinal surgery within 12 weeks, enteric infection within 2 weeks, a history of tuberculosis, a positive chest X-ray or tuberculin protein-purifi ed derivative skin test, active infection with hepatitis B or any infection with hepatitis C, infection with human immunodefi ciency virus, cancer within 5 years, inadequate bone marrow, hepatic, or renal function, a history of alcohol or drug abuse that would interfere with the study, signifi cant concurrent medical diseases, allergy to plants in the Acanthacea family, and women who were pregnant or breastfeeding were not eligible. Patients receiving oral or rectal steroids within 1 month, rectal mesalamine within 1 week, antibiotics within 2 weeks, or azathioprine, 6-mercaptopurine, anti-tumor necrosis factor agents, or immunosuppressive therapy within 6 weeks were also excluded.
Study design
Patients were randomly assigned to receive oral capsules containing A. paniculata ethanol extract (HMPL-004; Hutchison MediPharma Ltd., Shanghai, China) at doses of 1,200 mg or 1,800 mg or placebo, administered in three divided doses. Patients were treated for 8 weeks and followed through week 12. Randomization was performed centrally using a block randomization schedule stratifi ed by concurrent mesalamine use (yes or no) and country / geographic region (North East USA, Mid-East USA, South East USA, Western USA, Canada, Ukraine, and Romania). Oral mesalamine was continued at a stable dose.
Follow-up, effi cacy, and safety evaluations
A colonoscopy or fl exible sigmoidoscopy was performed and the Mayo Score was determined at weeks 0 and 8. A partial Mayo Score (Mayo Score without endoscopy) was determined at all visits between weeks 0 and 8 inclusive. Clinical response was defi ned as a decrease from baseline in the total Mayo Score by at least 3 points and at least 30 % with an accompanying decrease in rectal bleeding subscore of at least 1 point or a absolute rectal bleeding subscore of 0 or 1 point ( 12, 13 ) . Clinical remission was defi ned as a total Mayo Score of 2 points or lower, with no individual subscore exceeding 1 point ( 12, 13 ) . Mucosal healing was defi ned as a decrease from baseline in the endoscopy subscore by at least 1 point and an absolute endoscopy subscore of 0 or 1 point ( 12, 13 ) .
Adverse events and concomitant medications were followed through week 12. Blood samples were collected at weeks 0 and 8 for C-reactive protein (CRP) concentrations.
Statistical analysis
Th e primary effi cacy end point was clinical response at week 8. Secondary effi cacy end points included clinical remission at week 8; mucosal healing at week 8; time to partial Mayo Score response (defi ned as the time point at weeks 2, 4, 6, or 8 at which there was a decrease from baseline in the partial Mayo Score by at least 2 points); change from baseline in the partial Mayo Score at weeks 2, 4, 6, or 8; and the mean change from baseline in the total Mayo Score at week 8. Safety assessments on adverse events were conducted through week 12.
To control for a type I error of 0.05 or less, the primary end point analyses were conducted in a prespecifi ed, sequential manner. Th e global null hypothesis was that the proportions of patients with clinical response at week 8 would not be diff erent between the three treatment groups at a 0.05 (two-sided) significance level. If the global null hypothesis was rejected, then the combined A. paniculata dose groups, the A. paniculata 1,200 mg dose group, and the A. paniculata 1,800 mg dose group were compared with placebo at a 0.05 (two-sided) signifi cance level. If the global null hypothesis was not rejected, then the combined dose group and individual dose group comparisons with placebo were considered as not statistically signifi cant. Given the large number of prespecifi ed secondary effi cacy variables evaluated at multiple time points during the study, the P values for all secondary effi cacy variables should be considered as nominal, as no adjustments were made for multiple comparisons.
Demographic and baseline characteristics were compared with the use of the χ 2 or Fisher ' s exact test for categorical variables and with analysis of variance on van der Waerden normal scores for continuous variables. Th e statistical analysis plan stated that clinical response, clinical remission, and mucosal healing would be analyzed using logistic regression, and that last observation carried forward methodology would be used to handle missing data. At the request of regulatory authorities, the data were instead analyzed using the Cochran -Mantel -Haenszel test and missing data were handled using worst case methodology as described below. A two-sided Cochran -Mantel -Haenszel test with concurrent mesalamine use / non-use as strata was used to compare clinical response, clinical remission, and mucosal healing. Missing data were handled using a " worst case " intentionto-treat analysis in which patients with any missing component of the Mayo Score were considered not to be in clinical response, clinical remission, or to have mucosal healing. Given a signifi - A. paniculata 1,800 mg, and placebo vs. the combined A. paniculata dose groups were analyzed. Time to partial Mayo Score response was compared with Cox regression and the results expressed as a hazard ratio (HR), interpreted as an odds ratio with 95 % confi dence interval (CI). A cumulative incidence Kaplan -Meier plot was also created. Th e change from baseline in partial Mayo Score at weeks 2, 4, 6, and 8 by treatment group and the mean treatment diff erence (placebo minus A. paniculata with respect to change from baseline) were plotted by post-baseline visit for each treatment group along with 95 % CI at these assessment times. Th e earliest time at which the lower limit on the CI for the treatment diff erence above zero was defi ned to be the time to fi rst signifi cant partial Mayo Score diff erence. Th e mean treatment diff erences of Mayo Score change from baseline between placebo and A. paniculata treatment groups were tested using ANCOVA, with treatment as a fi xed eff ect, country / region as a random eff ect, and age, gender, race, baseline value, and concomitant mesalamine use as covariates. Safety comparisons used the Fisher ' s exact test. All patients receiving at least one dose of study medication were analyzed for safety according to the treatment actually received.
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To evaluate the consistency of treatment eff ect on clinical response between placebo, A. paniculata 1,200 mg, and A. paniculata 1,800 mg, 2 prespecifi ed subgroup analyses (concurrent mesalamine and country / region) and 7 post hoc subgroup analyses (gender, race, age, weight, disease duration, elevated CRP, baseline Mayo Score) were performed. P values were calculated based on the Pearson χ 2 test and 95 % CI ' s were based on the normal approximation to the binomial.
For the primary end point of clinical response at week 8, it was estimated that 202 patients would allow 80 % power to detect a diff erence in response rates of 21 % between the combined A. paniculata dose groups and the placebo group using the logistic regression analysis, assuming a 51 % rate of response to A. paniculata and a 30 % rate of response to placebo.
RESULTS

Characteristics of the patients
In total, 224 patients were randomized to treatment: 75 to placebo, 75 to the A. paniculata 1,200 mg daily, and 74 to A. paniculata 1,800 mg daily. One patient was incorrectly randomized and was excluded from the effi cacy analyses. Th e baseline disease characteristics were similar in the three groups ( Table 1 ). In all, 180 of 224 patients (80.7 % ) completed the 8-week trial ( Figure 1 ). . Th e following subgroups showed trends toward a greater A. paniculata response compared with placebo: Mayo Score < 6 points (primarily in the 1,200-mg group); endoscopy subscore < 2 points; CRP > 0.8 mg / dl; weight > 85 kg; patients from Europe (primarily in the 1,800-mg group); concomitant mesalamine use (primarily in the 1,800-mg group); disease duration > 5 years; white patients; patients aged 18 -45 years; and male patients. All subgroup comparisons in the pooled A. paniculata vs. placebo analysis showed distinct divergence with the exception of the baseline CRP subgroup. In the 1,200-mg vs. placebo subgroup analysis only the endoscopy subscore < 2 points ( P = 0.0241) and race ( P = 0.0780) subgroups were observed to be divergent. However, the 1,800-mg vs. placebo subgroup analysis showed distinct divergence in all subgroups with the exception of the baseline CRP subgroup. Disease duration was not confounded within age group as there was little diff erence in disease duration across the age group categories.
Effi cacy
Primary
Secondary end points . In total, 36 % of patients receiving A. paniculata (53 of 148) were in clinical remission at week 8 as compared with 25 % receiving placebo (19 of 75) ( P = 0.1173; Table 2 ). Th e rates of clinical remission for the 1,800-and 1,200-mg doses were not signifi cantly greater than placebo, although there was a trend toward signifi cance for the 1,800-mg dose, P = 0.1011. Th e results of logistic regression analysis using last observation carried forward methodology were generally similar to the worst case methodology, but using this analysis the diff erence between A. paniculata 1,800 mg and placebo was signifi cant ( Supplementary Table 1 ).
In all, 44 % of patients receiving A. paniculata (65 of 148) achieved mucosal healing at week 8 as compared with 33 % receiving placebo (25 of 75) ( P = 0.1309; Table 2 ). A dose response for A. paniculata was demonstrated; the rate of mucosal healing for the 1,800-mg dose was signifi cantly greater than placebo whereas the 1,200-mg dose was not. Th e results of logistic regression analysis using last observation carried forward methodology were similar ( Supplementary Table 1 ) .
Th e times to fi rst signifi cant diff erence in partial Mayo Score response and fi rst signifi cant partial Mayo Score response were both 4 weeks in the combined A. paniculata groups, 4 weeks in the A. paniculata 1,800 mg group, and 4 weeks in the A. paniculata 1,200 mg group. Th e HR for the time to fi rst signifi cant difference in partial Mayo Score response was 1.57 ( P = 0.0096) for
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Andrographis paniculata for Ulcerative Colitis the combined A. paniculata groups over placebo; the HRs for the 1,800-mg and 1,200-mg groups were 1.72 ( P = 0.0060) and 1.44 ( P = 0.0679), respectively. Th e cumulative incidence KaplanMeier plot is shown in Figure 2 . Th e mean improvement (95 % CIs) from baseline in the total Mayo score at week 8 between placebo and A. paniculata from the ANCOVA model was 0.51 ( − 0.33, 
Safety
Th rough week 8, the incidence of adverse events was generally similar among groups ( Table 3 ) . A rash occurred in 8 % of patients receiving A. paniculata and 1 % of patients receiving placebo. Th e rashes were mostly mild (with the rest moderate), reversible, and did not cause treatment discontinuation.
DISCUSSION
Treatment with A. paniculata extract (HMPL-004) was more eff ective than placebo for induction of clinical response and mucosal healing at week 8 among patients with mildly to moderately active ulcerative colitis, most of whom were failing fi rstline therapy with mesalamine. Th e best effi cacy was observed with the 1,800-mg dose. However, there were no signifi cant differences between the A. paniculata and placebo groups in the worst case scenario analyses of clinical remission rates or mean improvement in total Mayo score at week 8. Th e end point of clinical remission was signifi cant with the last observation carried forward analysis. Subgroup analysis indicated trend toward greater clinical response rates in subgroups of patients treated with A. paniculata who had baseline Mayo score < 6 points and those with an endoscopy subscores < 2 points; this was most apparent in those patients treated with the 1,200-mg dose. Age, gender, and geographic region were also assessed as covariates of clinical response. Th ere was signifi cant subgroup-by-treatment interaction observed in the 1,200-mg group for the baseline endoscopy subscore and race. Th ere was also a trend toward a better clinical response to patients treated with A. paniculata in subgroups of patients with younger age, male sex, and European geographic location. A statistically signifi cant improvement in clinical response was not observed in patients with North American geographic location. Th ese subgroup analysis results should be interpreted with caution due to limited power based on small number of study subjects. Th e HRs for the time to fi rst significant diff erence in partial Mayo Score response were greater in the A. paniculata -treated patients, but in the Kaplan -Meier analysis, the response rates equalized at week 8. 
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Andrographis paniculata for Ulcerative Colitis
A previous pilot study demonstrated that treatment with A. paniculata 1,200 mg daily for 8 weeks resulted in a similar reduction from baseline in disease activity to that observed with oral mesalamine in patients with mildly to moderately active ulcerative colitis ( 10 ) . We also found preliminary evidence of effi cacy for A. paniculata 1,200 mg daily for 8 weeks as compared with placebo in patients with mildly to moderately active Crohn ' s disease ( 14 ) . In the current study, we demonstrated dose response with A. paniculata 1,200 mg and 1,800 mg daily and no dose-dependent toxicity. Additional clinical trials to evaluate the safety and effi cacy of even higher doses of A. paniculata extract (HMPL-004) should be undertaken in both ulcerative colitis and Crohn ' s disease.
Subgroup analysis showed a larger therapeutic eff ect for A. paniculata extract (HMPL-004) relative to placebo in patients who were currently failing oral mesalamine, and a smaller and non-signifi cant eff ect relative to placebo among patients not receiving mesalamine. Th is latter result appears largely due to a greater rate of placebo response among patients not receiving mesalamine. Th is subgroup of patients was relatively small, and the study lacked suffi cient statistical power to draw any meaningful conclusions regarding the effi cacy of A. paniculata in this patient population. Additional adequately powered studies to assess the effi cacy of A. paniculata extract (HMPL-004) as monotherapy in patients with ulcerative colitis are warranted. It should also be noted that the effi cacy of A. paniculata extract (HMPL-004) for Adverse events leading to study drug discontinuation, n ( % ) support for travel to meetings for the study and other purposes, receiving fees for review activity related to data monitoring and analysis, and for writing and reviewing the manuscript. Mr. Rutty reports having received the following from Hutchison Medipharma: support for travel to meetings for the study and other purposes, receiving fees for review activity related to data monitoring and analysis, and for writing and reviewing the manuscript. In addition, he reports Board membership for Steba Biotech SA and reports consulting for the folinduction therapy in patients with ulcerative colitis who are failing various combinations of corticosteroids, azathioprine, and antitumor necrosis factor therapy with infl iximab is unknown, as its effi cacy as a maintenance agent. Additional studies in these patient populations are also needed. Th e 40 % placebo response rate in our study was slightly higher than expected. Th is study was patterned aft er two randomized double-blind placebo-controlled studies of infl iximab in ulcerative colitis ( 12 ) . In the fi rst of these studies, the week 8 response rate was about 40 % and in the second study the analogous response rate was 30 % . Th e placebo response in our study was in this same general range. In the infl iximab trials, the entry criteria specifi ed baseline Mayo Scores of 6 -12 points. In our study, the baseline Mayo Scores were 4 -10 points, which may also have infl uenced the placebo response rate. Experience with the use of real-time central reading of endoscopy in clinical trials to reduce placebo rates is evolving, and in future trials central reading could potentially reduce the relatively high placebo rates that we observed in this trial.
In this short-term study, the overall incidence of adverse events observed in patients treated with A. paniculata extract (HMPL-004) was similar to patients receiving placebo, with the exception of rash which was higher in the A. paniculata extract (HMPL-004) groups. Longer term studies are needed to further assess the safety and tolerability of A. paniculata extract (HMPL-004) in patients with ulcerative colitis. If such studies continue to demonstrate a favorable safety profi le, then it may be possible to combine A. paniculata extract (HMPL-004) with other drugs of known effi cacy such as corticosteroids, azathioprine, and anti-tumor necrosis factor agents, with the goal of achieving synergistic effi cacy without incurring synergistic toxicity.
Th e mechanism of action of A. paniculata extract should be further explored. In vitro inhibitory activity against TNF-α , IL-1 β , and NF-κ B has been reported ( 8, 9 ) . Additional preclinical studies in animal models of colitis should be undertaken to further explore the effi cacy and biologic eff ects of A. paniculata extract and its major active components the diterpene lactones such as andrographolide across a range of doses.
In conclusion, patients with mildly to moderately active ulcerative colitis treated with A. paniculata extract (HMPL-004) were more likely to achieve clinical response than those receiving placebo. 
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